Compare ALSN & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALSN | CYTK |
|---|---|---|
| Founded | 1915 | 1997 |
| Country | United States | United States |
| Employees | 4000 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 10.7B |
| IPO Year | 2011 | 2004 |
| Metric | ALSN | CYTK |
|---|---|---|
| Price | $122.71 | $71.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | ★ $117.57 | $89.26 |
| AVG Volume (30 Days) | 779.8K | ★ 1.9M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $3,010,000,000.00 | $13,368,000.00 |
| Revenue This Year | $94.98 | $7.37 |
| Revenue Next Year | $5.30 | $310.19 |
| P/E Ratio | $36.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $76.01 | $47.22 |
| 52 Week High | $137.62 | $88.31 |
| Indicator | ALSN | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 38.45 |
| Support Level | $110.38 | $59.19 |
| Resistance Level | $124.74 | $79.66 |
| Average True Range (ATR) | 3.81 | 2.17 |
| MACD | -0.64 | -0.45 |
| Stochastic Oscillator | 6.21 | 26.41 |
Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.